Cholecystokinin (CCK)-like immunoreactivity (CCK-LI) in a pool of 12 dog brains was extracted sequentially into boiling water and cold 2% trifluoroacetic acid. Gel filtration on Sephadex G-50 revealed three main molecular forms detected by a carboxyl-terminal antibody; one was eluted in the position of CCK-58 (58 amino acid residues long); a second, in the position of CCK-8; and a third, near the radioactive iodide marker. When the CCK-LI was purified by affinity chromatography using carboxyl-terminal CCK antibody followed by three steps of reversed-phase high-pressure liquid chromatography, three components were isolated and characterized by sequence microanalysis. The smallest component was the pentapeptide common to gastrin and CCK. The second peak was eluted in the same region as synthetic CCK octapeptide, and sequence analysis showed that the chemical structure of this biologically active region of canine CCK is identical to that found in sheep and pig brains. The 22-residue aminoterminal sequence of brain CCK-58 was: Ala-Val-Gln-LysVal-Asp-Gly-Glu-Pro-Arg-Ala-His-Leu-Gly-Ala-LeuLeu-Ala-Arg-Tyr-Ile-Gln-, the same as the sequence found for canine intestinal CCK-58 from this pool of dogs. This is the same sequence others have reported for porcine brain CCK-58 lacking nine amino acid residues (CCK-58 desnonapeptide) except that the porcine peptide had a serine in position 9. The canine CCK amino-terminal sequence differed from the se-
canine intestinal CCK-58 from this pool of dogs. This is the same sequence others have reported for porcine brain CCK-58 lacking nine amino acid residues (CCK-58 desnonapeptide) except that the porcine peptide had a serine in position 9 . The canine CCK amino-terminal sequence differed from the sequence Ala-Gln-Lys-Val-Asn-Ser previously reported for intestinal CCK-58 purified from another pool of dog tissue, but the rest of the residues identified were identical in the two peptides. CCK-58 may be a molecular precursor of the smaller forms of CCK in brain as well as in gut.
Cholecystokinin (CCK) immunoreactivity has been found in brain and gut of several species including human, monkey, dog, pig, rat, and frog (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . Cholecystokinins that contain 39 and 33 amino acid residues (CCK-39 and CCK-33) have been characterized in the pig intestine (12, 13) . Recently a canine intestinal cholecystokinin that was eluted on Sephadex G-50 gel filtration before CCK-39 was found to possess 19 additional amino acids at the amino terminus of CCK-39 and was termed CCK-58 (7) . In the brain, small molecular forms of CCK with carboxyl-terminal immunoreactivity are relatively more abundant than large forms. The predominant form of CCK in the brain was eluted on gel filtration in the position of CCK octapeptide, and CCK-8 has been sequenced from sheep (5) and porcine brain (6) . The largest CCK component was found in canine (3, 10)-. porcine (3, 6, 10)-, rat (3)-, and frog (11)-brain elutes on gel filtration before CCK-39, and it is possibly a common precursor to all CCK forms. This large form has been identified as CCK-58 (58 amino acids) in canine intestine (7) and CCK-58 lacking nine amino acid residues (CCK-58 desnonapeptide) in porcine brain (6) . We present here the partial amino acid sequence of this CCK peptide isolated from canine brain, which was found to be biologically active and identical in structure to intestinal CCK-58 isolated from the same pool of dogs and to be similar but not identical to the previously characterized canine intestinal CCK-58 (7). METHOD Extraction and Purification. Twelve mongrel dogs were killed after a 24-hr fast by pentobarbital overdose. The entire brain was obtained within 10 min after death. The brain was immediately frozen and stored at -20'C until extraction.
Frozen brain tissue (2 kg) was broken into 10-to 20-g pieces, then blended in a Polytron homogenizer with 2 vol of water, and added to another three vol of boiling water. The extract was boiled for 10 min and allowed to cool; then CF3COOH was added to a final concentration of 2%, and the extract was stirred for 6 hr at 40C. The extract was then centrifuged at 2000 x g for 1 hr. The supernatant was adjusted to pH 5.0 by addition of concentrated ammonium hydroxide and then centrifuged again under the same conditions for 1 hr. Affinity Chromatography. Affinity chromatography was done as described for rat gastrin (14) , except a different carboxyl-terminal antibody (8105) was coupled to Affi-Gel 10. Before extracts were added, the column was eluted with 4% CF3COOH. No CCK immunoreactivity was detected in this eluate, indicating that <5 pmol of CCK was bound to the column prior to addition of intestinal extract.
High-Performance Liquid Chromatography. Affinity-purified brain extract was further purified by HPLC on three successive HPLC columns. The immunoreactive CCK pools were applied to a reversed-phase C18 HPLC column (Waters Radial-Pak tkBondapak C18, 10 ,um; 8 mm x 10 cm), equilibrated with solvent A (0.1% trifluoroacetic acid) and rinsed with the same solution until the absorbance at 280 nm returned to baseline. The column was eluted with a linear gradient from 100% solvent A to 100% solvent B (999 ml of 50% acetonitrile/50% water with 1 ml of CF3COOH) over 100 min with a flow rate of 1 ml/min. The immunoreactive peak was sequentially purified on a reversed-phase alkylphenyl HPLC column (Waters ,uBondapak, 10 ,um; 3.9 mm x 30 cm) and a Vydac reversed-phase C18 column (Vydac, 5 ,.tm; 4.6 mm x 25 cm). Gradients were chosen by elution positions on the previous columns.
Radioimmunoassay. CCK-like immunoreactivity (CCK-LI) was measured throughout the purification procedure by a RIA using antibody 5135 as described (15) . This antibody is specific for the carboxyl-terminal region of CCK and gastrin and crossreacts 25% with their common pentapeptide.
Amino Acid Analysis. Approximately 0.1-0.2 nmol of peptides was hydrolyzed in 6 M HCl/0.02% 2-mercaptoethanol Abbreviations: CCK, cholecystokinin; CCK-LI, cholecystokininlike immunoreactivity; CCK fragments are indicated by the number of amino acid residues they contain; des indicates the number of amino acid residues removed.
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for 24 hr at 1100C. Hydrolysates were applied to a Beckman 121MB analyzer as described (16) .
Sequence Analysis. Samples obtained from HPLC purification were subjected to automated Edman degradation on a modified Beckman 890C sequencer (17) , and phenylthiohydantoin derivatives of amino acids were analyzed by HPLC as described (18) .
Analytical Gel Permeation Chromatography. Aliquots (1 ml) of the brain extracts were applied to Sephadex G-25 gel chromatography columns (1 x 100 cm) and eluted with 0.1% CF3COOH/0.1% human serum albumin at a flow rate of -6 ml per hour.
RESULTS
Recovery of immunoreactive CCK, measured by carboxylterminal antibody 5135, is shown for each purification step in Table 1 . Between 79% and 100% of CCK-LI was recovered during purification except for the first C18 HPLC step. The CCK-LI of the crude brain extract was eluted during Sephadex G-25 gel filtration as two major peaks (Fig. 1) ; the first was eluted before CCK-39 and the second, in the region of CCK-8. About 21% of total CCK-LI was found in the early elution position. No immunoreactivity was detected in the column eluate with the gastrin-specific antibody 1611.
After affinity chromatography of the crude extract, the CCK-LI was eluted as one broad peak from the Radial-Pak HPLC (not shown); the peak was separated into several distinctive peaks by subsequent chromatography on an alkylphenyl column ( Fig. 2 and Table 2 ). The most abundant immunoreactive peak (pool e), when further purified on a Vydac C18 column by using a gradient from 50% to 70% solvent B over 40 min, was coeluted with synthetic sulfated CCK-8 at 59% solvent B. It also was eluted with synthetic sulfated CCK-8 when equal amounts were eluted isocratically (results not shown). The ratio of peptide measured by RIA and by absorbance at 280 nm was about 1, the same value obtained for synthetic sulfated CCK-8. Amino acid analysis on 200 pmol of this peak was consistent with the amino acid composition of CCK-8: Asp2.0Gly1.5Met1.5TyrO.9PheO.9 and less than 0.4 residues for all other amino acids. Trace amounts of tryptophan were present, which is expected for acid hydrolysis, and sequence analysis of 1.8 nmol of immunoreactive material revealed the sequence of CCK-8.
In the eluate of the alkylphenyl column (Fig. 2 and Table  2 ), several other CCK immunoreactive peaks were detected. The first immunoreactive peak (pool a) was purified, and subsequent sequence microanalysis revealed it to be the pen- Elution profile from Sephadex G-25 superfine (1 x 100 cm) of canine CF3COOH brain extract (1 ml). The column was eluted with 0.1% CF3COOH containing 0.1% human serum albumin, and 1-ml fractions were collected. Immunoreactive CCK was measured with carboxyl-terminal antibody 5135. tapeptide common to CCK and gastrin. The RIA/A ratio (explained in Table 1 ) of the peptide was 0.28. The second immunoreactive peak that was eluted from the alkylphenyl column (pool b) was not sequenced because it was not judged to be pure, but the RIA/A ratio suggested that it was a peptide larger than CCK-5 (its crossreaction with antibody 5135 was 0.5 even though it was clearly not a homogeneous peak). The third peak (pool c) from the alkylphenyl column was purified on a Vydac column, and the sequence microanalysis of this peak revealed the same sequence of CCK-8. Since methionine-oxidized forms of CCK are eluted earlier on this column, this CCK-8 may represent an oxidized form. The fourth peak (pool d) was coeluted from the subsequent Vydac column with sulfated synthetic CCK-8 but was still contaminated with other peptides and was not further characterized.
The sixth peak (pool f) that was eluted from the alkylphenyl column was purified on a Vydac column (Table 1) and gave single absorbance peaks at 220 and 280 nm, was eluted in the same region as canine intestinal CCK-58 isolated in the same way from the same pool of dogs, and contained all of the CCK immunoreactivity. The RIA/A ratio for this brain peptide was 0.35, similar to that found for intestinal CCK-58. Amino acid sequencing was performed on 500 pmol of this component and gave an initial yield of 238 pmol (48%). A sudden drop in yields was observed at cycle 6 (aspartic acid residue). The data presented (Fig. 3) show Asp at position 6 but also could be consistent with an Asn-Gly bond since the Asn-Gly could form an isoamide bond which cannot be sequenced. Once formed, the isoamide bond could open to give Asp-Gly. Thus, the low yield and the Asp could come from an Asn-Gly bond. Glycine is probably necessary for this rearrangement or deamidation since no drop in yield was observed for the sequence Asn-Ser in canine gut CCK-58 (7). Sequence analysis was possible through 22 Ala-Val-Gln-Lys -Val-Asp-Gly-Glu-Pro-Arg -Ala-His- 15 20 Leu-Gly -Ala-Leu-Leu-Ala-Arg -Tyr-lie -GIn- 3). After this point the yields were too low for definite identification of phenylthiohydantoin derivatives. The first 22 amino-terminal residues were identical to those of CCK-58 isolated from dog intestinal mucosa from this pool of dogs. They were also identical to intestinal CCK-58 previously isolated from another pool of dogs except that the first six residues showed an insertion of Val in position 2, a possible (Fig. 4) . No CCK-58 remained from the previous isolation, and slightly different elution gradients were used, so no direct comparisons of the CCK-58 from different pools of dogs could be made. Amino acid analysis on this material was not performed because of the low amounts of peptide present. The biological activity of brain CCK-58 was tested in isolated perfused pancreatic mouse acini and found to be equal to that of synthetic sulfated CCK-8 (C. Deveney, personal communication).
DISCUSSION
The present study describes the isolation and characterization of identical CCK-58 sequences from canine brain and intestine from a pool of 12 mongrel dogs. This sequence is also identical to porcine brain CCK-58 desnonapeptide except that the porcine peptide had a serine in position 9 (6) . This sequence differs from that previously described for CCK-58 from another set of nine mongrel dog intestines (7) . Positions 2-6 of the amino-terminal sequence of canine brain CCK-58 (-Val-Gln-Lys-Val-Asp-) differed from the CCK-58 previously isolated from canine intestine (-Gln-Lys-Val-Asn- Biochemistry: Eysselein et aL
Structures of mammalian CCK-58 sequences. Canine brain CCK forms were isolated, sequenced, and compared to structures of canine intestine and porcine brain and intestine. The parenthesis enclosing the carboxyl-terminal region of porcine brain CCK indicates these residues were assigned as a result of amino acid analysis and homology to porcine intestinal CCK-33, but no sequence data were obtained directly. A dashed line indicates that there are no sequence data for these positions, but they are assumed to be present because of crossreactions with carboxyl-terminal CCK antibodies. *The data for porcine brain CCK were taken from ref. 6. Ser-), but the other 17 residues identified were identical. Since both peptides contain -Gln-Lys-Val-, it can be appreciated that a deletion of Val, insertion of Ser, and a Asn,Asp substitution changes the brain peptide into the previously described intestinal peptide. The Asn,Asp substitution may reflect a deamidation during isolation, a deamidation within the cell, or a true genetic substitution. The changes could reflect an error during sequence analysis, but this is unlikely since there was a carryover into the next cycle of every phenylthiohydantoin derivative for both analyses. It is also possible that the changes reflect intraspecies polymorphism similar to that shown for vasopressin from wild boar (19) , where eight individuals contained [Arg8]vasopressin alone, two contained [Lys8]vasopressin, and eight contained both vasopressins. These studies were done with individuals and not pools as in our studies. It is difficult to explain how CCK from one pool of dogs would vary from another pool of dogs. The reason for the differences in sequences of the intestinal CCKs is unknown at this time.
Several groups have described CCK-LI that is eluted before CCK-39 during gel filtration chromatography of brain extracts from dog (3, 10), pig (3, 4, 10) , rat (3), and frog (11) . Our chemical characterization of CCK-58 peaks shows that the CCK-LIs that are eluted early are not smaller CCK fragments absorbed onto protein. Others have failed to find evidence for such a large CCK peptide in pig (9), rat (20) , or human (8, 9) brain extracts. These immunochemical results may reflect (i) differences in extraction procedures (the large, basic CCK peptides are preferentially extracted by acid and not by water), (ii) losses of large CCK peptides during sample preparation or column chromatography due to absorption, or (iii) differences in antibodies used. Alternatively, as best shown for human brain, the period from death until the brain is frozen may vary, and large CCK peptides may be enzymatically converted to smaller molecules.
The biologically active octapeptide of CCK was the predominant form characterized from dog, human (8) , sheep (5) , and pig (6) brain. Pig and dog intestinal mucosa CCK forms differ from brain forms by the presence of significant amounts of intact CCK-33 and -39. Brain CCK may be more quickly processed from large (CCK-58) to intermediate (CCK-39 and -33) to small forms (CCK-8 and -5), or there may be another set of enzymes present that directly converts the brain large forms into the small forms (21) . The major CCK-LI peak that is eluted near the salt region on Sephadex G-25 gel permeation columns is the carboxyl-terminal octapeptide of CCK; the minor, diffuse peak that is eluted after CCK-8 is presumably the carboxyl-terminal pentapeptide of CCK. Previously CCK-8 has been chemically characterized from sheep (5) and pig (6) brain. CCKs smaller than CCK-8 have been strongly supported (22) CCK-58 represented at least 13-20% of total immunoreactivity recovered from gel permeation or HPLC separations. These may be low estimates of its true proportion in cells because CCK-58 does not crossreact as well as octapeptide with antibody 5135. The high proportions of CCK-58 suggest that it is an important CCK form in brain as well as in gut.
